\centered **AMENDMENT**

^ \centered **TO** 
^^ \centered **REGISTRATION RIGHTS AGREEMENT** 

**THIS AMENDMENT TO REGISTRATION RIGHTS AGREEMENT** (this “Amendment”) is made and entered into as of [[Date 1: Date]] by and among **TECHNISCAN, INC**., (the “Issuer”) and **BIOTEX PHARMA INVESTMENTS** (the “Lead Investor”).

\centered R E C I T A L S:

**WHEREAS,** the Issuer and the Lead Investor desire to revise that certain Registration Rights Agreement dated [[Date 2: Date]] entered into by and among the Issuer, the Lead Investor, and the other holders listed on Schedule I thereto (the “Agreement”).

**NOW, THEREFORE,** in consideration of the foregoing and the mutual benefits to be derived from this Amendment, the parties hereto hereby agree as follows:

^Amendment of the Agreement. Pursuant to Section 10 of the Agreement, the Agreement is hereby amended as follows:

^^In Section 1, the definition for “***Effectiveness Deadline***” shall be revised as follows:

*The number 105**th* *shall be deleted and replaced with the number 120**th**, and the number 150**th* *shall be deleted and replaced with the number 165**th**.*

^^In Section 1, the definition for “***Filing Deadline***” shall be revised as follows:

*The number 45**th* *shall be deleted and replaced with the number 60**th**.*

^Continued Effect of the Agreement. All provisions of the Agreement, except as modified by this Amendment, shall remain in full force and effect and are reaffirmed. Other than as stated in this Amendment, this Amendment shall not operate as a waiver of any condition or obligation imposed on the parties under the Agreement.

^Interpretation of Amendment. In the event of any conflict, inconsistency, or incongruity between any provision of this Amendment and any provision of the Agreement, the provisions of this Amendment shall govern and control.

^Counterparts. This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same agreement. A facsimile or 

e-mailed “.pdf” data file copy of an original written signature shall be deemed to have the same effect as an original written signature.

**IN WITNESS WHEREOF**, the parties hereto have executed this Amendment to Registration Rights Agreement as of the date first set forth above.

**TECHNISCAN, INC.**      **BIOTEX PHARMA INVESTMENTS**

[[TECHNISCAN INC.      BIOTEX PHARMA INVESTMENTS Signatory Email: Identity | Signature]]
__________________________________________
{{TECHNISCAN INC.      BIOTEX PHARMA INVESTMENTS Entity => By: [[TECHNISCAN INC.      BIOTEX PHARMA INVESTMENTS Signatory First Name]] [[TECHNISCAN INC.      BIOTEX PHARMA INVESTMENTS Signatory Last Name]]
Title: [[TECHNISCAN INC.      BIOTEX PHARMA INVESTMENTS Signatory Title]]}}

David C. Robinson

Chief Executive Officer      Print Name:   Robert Kessler

Title:   Member